Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 20/20 | 0.69 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13638060 | 1.00 | TACR1 (0.69) | TACR1NR1I2KCNH2CYP3A4CYP2D6 | |
| SCHEMBL13631266 | 1.00 | TACR1 (0.69) | TACR1NR1I2KCNH2CYP3A4CYP2D6 | |
| SCHEMBL13638050 | 1.00 | TACR1 (0.69) | TACR1NR1I2KCNH2CYP3A4CYP2D6 | |
| SCHEMBL4452285 | 1.00 | TACR1 (0.69) | TACR1NR1I2KCNH2CYP3A4CYP2D6 | |
| SCHEMBL13631180 | 1.00 | TACR1 (0.69) | TACR1NR1I2KCNH2CYP3A4CYP2D6 | |
| SCHEMBL4462489 | 0.94 | TACR1 (0.70) | TACR1NR1I2KCNH2CYP3A4CYP2D6 | |
| SCHEMBL4462484 | 0.94 | TACR1 (0.70) | TACR1NR1I2KCNH2CYP3A4CYP2D6 | |
| SCHEMBL13631265 | 0.93 | TACR1 (0.68) | TACR1NR1I2KCNH2CYP3A4CYP2D6 | |
| SCHEMBL13638049 | 0.93 | TACR1 (0.68) | TACR1NR1I2KCNH2CYP3A4CYP2D6 | |
| SCHEMBL13631182 | 0.93 | TACR1 (0.68) | TACR1NR1I2KCNH2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286777-A1 | 5,6,Fused Pyrrolidine Compounds Useful as Tachykinin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286777-A1 | 5,6,Fused Pyrrolidine Compounds Useful as Tachykinin Receptor Antagonists | TACR1, TACR2, NPSR1 | TACR1 1/4885NR1I2 2873/4885KCNH2 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.